Novartis AG Operating Expenses 2010-2022 | NVS

Novartis AG annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Novartis AG operating expenses for the quarter ending June 30, 2022 were $10.857B, a 10.62% increase year-over-year.
  • Novartis AG operating expenses for the twelve months ending June 30, 2022 were $41.913B, a 3.22% increase year-over-year.
  • Novartis AG annual operating expenses for 2021 were $41.188B, a 3.63% increase from 2020.
  • Novartis AG annual operating expenses for 2020 were $39.746B, a 0.39% increase from 2019.
  • Novartis AG annual operating expenses for 2019 were $39.591B, a 5.03% increase from 2018.
Novartis AG Annual Operating Expenses
(Millions of US $)
2021 $41,188
2020 $39,746
2019 $39,591
2018 $37,696
2017 $41,506
2016 $41,168
2015 $41,410
2014 $42,545
2013 $41,733
2012 $40,464
2011 $48,595
2010 $40,035
2009 $35,121
Novartis AG Quarterly Operating Expenses
(Millions of US $)
2022-06-30 $10,857
2022-03-31 $9,962
2021-12-31 $10,960
2021-09-30 $10,134
2021-06-30 $9,815
2021-03-31 $10,279
2020-12-31 $10,386
2020-09-30 $10,126
2020-06-30 $9,270
2020-03-31 $9,964
2019-12-31 $10,893
2019-09-30 $10,124
2019-06-30 $9,361
2019-03-31 $9,213
2018-12-31 $10,535
2018-09-30 $9,147
2018-06-30 $9,222
2018-03-31 $8,792
2017-12-31 $11,094
2017-09-30 $10,335
2017-06-30 $10,214
2017-03-31 $9,863
2016-12-31 $11,151
2016-09-30 $10,072
2016-06-30 $10,586
2016-03-31 $9,359
2015-12-31 $11,127
2015-09-30 $10,251
2015-06-30 $10,615
2015-03-31 $9,417
2014-12-31 $11,003
2014-09-30 $10,561
2014-06-30 $10,765
2014-03-31 $10,216
2013-12-31 $9,828
2013-09-30 $10,348
2013-06-30 $10,247
2013-03-31 $11,310
2012-12-31 $6,763
2012-09-30 $11,091
2012-06-30 $11,433
2012-03-31 $11,177
2011-12-31 $13,897
2011-09-30 $12,083
2011-06-30 $11,801
2011-03-31 $10,814
2010-12-31 $11,997
2010-09-30 $10,233
2010-06-30 $8,960
2010-03-31 $8,845
2009-12-31 $10,508
2009-09-30 $8,656
2009-06-30 $8,378
2009-03-31 $7,579
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.828B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84